Royalty Pharma ROE 2019-2021 | RPRX
Current and historical return on equity (ROE) values for Royalty Pharma (RPRX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
|Royalty Pharma ROE - Return on Equity Historical Data
||TTM Net Income
||Return on Equity
||Finance - Miscellaneous Services
Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.